Table 1.

Study and patient characteristics – switching and discontinuation patterns among triptan users

Citation	Country (Study period)	Study type	Study name/ database	Sample	Subgroup	n	Mean age, yrs	% female
Alam, 2018 [35]	US (2016)	Multicenter cross-sectional, Survey	MAST study	Current users	Overall	15,133	43.1	73.0
Chen, 2014 [36]	Taiwan (2005-2008)	Database study	NHIR Database	Incident users	Overall	13,951	41.3	77.0
Fischer, 2016 [37]	Austria (2009-2012)	Single center chart review	Outpatient clinic, U of Innsbruck	Incident users (first/new agent)	Overall	126	37.2	88.1
Katic, 2011 [38]	US (2001-2005)	Database study	i3 InVision Data Mart	Incident users	Overall	40,892	37.8	78.9
Lombard, 2018 [39]	US (2012-2014)	Database study	Truven MarketScan	Incident users	Overall	124,556	30.0-49.0	81.0
Ng-Mak, 2012 [40]	EU (2006-2008)	Database study	IMS Disease Analyzer	Incident users	UK	3618	41.3	75.6
					France	2051	38.9	75.8
					Germany	954	41.6	78.0
Serrano, 2013 [41]	US (2005-2009)	Multicenter prospective, Survey	AMPP study	Current users	Consistency group A	700	47.3	89.0
					Consistency group B	697	47.2	88.5
					Consistency group C	687	47.1	88.6

Consistency group A: Did not switch to another triptan in any couplet and consistently used the same triptan across years in their first eligible couplet; Consistency group B: Did not switch to an opioid/ barbiturate in any couplet and consistently used the same triptan across years in their first eligible couplet; Consistency group C: Did not switch to an NSAID in any couplet and consistently used the same triptan across years in their first eligible couplet

Abbreviations: AMPP American Migraine Prevalence and Prevention, EU Europe, IMS Information Management System, MAST Migraine in America Symptoms and Treatment, NHIR National Health Insurance Research, SC Subcutaneous inj., U University, US United States, Yrs Years